{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:58:01Z","timestamp":1777420681182,"version":"3.51.4"},"reference-count":17,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T00:00:00Z","timestamp":1551225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:p>Objective: To review the mechanism of action, clinical efficacy, safety, dosage, administration, and role of copanlisib in the treatment of relapsed follicular lymphoma (FL). Data Sources: Sources of information were identified through searches of PubMed (August 2014 to January 2019) using the key terms copanlisib, Aliqopa, PI3K inhibitor, and BAY 80-6946. Unpublished abstract information was obtained from the American Society of Clinical Oncology. Study Selection and Data Extraction: Review articles and studies in the English language evaluating the pharmacology, efficacy, and safety of copanlisib were included. Data Synthesis: Copanlisib is the first intravenous phosphatidylinositol 3-kinase (PI3K) inhibitor approved for the treatment of relapsed FL in patients who have received at least 2 prior systemic therapies. The safety and efficacy of copanlisib has been studied in the multicenter, single-arm, phase II CHRONOS-1 study. The results reported for FL patients were an objective response rate of 59%, a complete response of 14%, median duration of response of 22.6 months, and median progression-free survival of 11.2 months. The most common adverse events reported were hyperglycemia and hypertension, which were infusion related and transient. Relevance to Patient Care and Clinical Practice: Copanlisib is unique in that it is a pan\u2013class I PI3K inhibitor with preferential inhibitory activity against the PI3K-\u03b1 and PI3K-\u03b4 isoforms. It has a more favorable safety profile than the other agents in its class with no late-onset toxicities. Conclusions: Copanlisib provides an alternative option for patients with relapsed FL. It is safe and effective and has an acceptable toxicity profile.<\/jats:p>","DOI":"10.1177\/1060028019833992","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T01:31:12Z","timestamp":1551317472000},"page":"954-958","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":23,"title":["Copanlisib: An Intravenous Phosphatidylinositol 3-Kinase (PI3K) Inhibitor for the Treatment of Relapsed Follicular Lymphoma"],"prefix":"10.1177","volume":"53","author":[{"given":"Adel","family":"Eltantawy","sequence":"first","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, Hollywood, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ximena","family":"Vallejos","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, Hollywood, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elrodia","family":"Sebea","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, Hollywood, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten","family":"Evans","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, Hollywood, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,2,27]]},"reference":[{"key":"bibr1-1060028019833992","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-624288"},{"key":"bibr2-1060028019833992","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr388"},{"key":"bibr3-1060028019833992","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-702761"},{"key":"bibr4-1060028019833992","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0716"},{"key":"bibr5-1060028019833992","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-352492"},{"key":"bibr6-1060028019833992","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0993-T"},{"key":"bibr7-1060028019833992","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw282"},{"key":"bibr8-1060028019833992","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.12.003"},{"key":"bibr9-1060028019833992","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3198-0"},{"key":"bibr10-1060028019833992","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx289"},{"key":"bibr11-1060028019833992","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4648"},{"key":"bibr12-1060028019833992","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.7536"},{"key":"bibr13-1060028019833992","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2015-CT212"},{"key":"bibr14-1060028019833992","unstructured":"Aliqopa [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; 2017."},{"key":"bibr15-1060028019833992","first-page":"4042","volume":"130","author":"Zinzani PL","year":"2017","journal-title":"Blood"},{"key":"bibr16-1060028019833992","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.11.021"},{"key":"bibr17-1060028019833992","unstructured":"Copiktra [package insert]. Needham, MA: Verastem Inc; 2018."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028019833992","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028019833992","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028019833992","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:54Z","timestamp":1777374894000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/1060028019833992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,27]]},"references-count":17,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,5,18]]},"published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1177\/1060028019833992"],"URL":"https:\/\/doi.org\/10.1177\/1060028019833992","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,27]]}}}